专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100159486A1 BIOMARKERS FOR NEUROLOGICAL CONDITIONS 审中-公开
标题翻译：生物标志物用于神经病学条件
公开(公告)号：US20100159486A1
公开(公告)日：2010-06-24
申请号：US12513032
申请日：2007-11-01
申请人： Lance A. Liotta , Wediong Zhou , Wolff Kirsch , Virginia Espina , Emanuel Petricoin, III , Mark Ross , Claudius Mueller , Shino Magaki
发明人： Lance A. Liotta , Wediong Zhou , Wolff Kirsch , Virginia Espina , Emanuel Petricoin, III , Mark Ross , Claudius Mueller , Shino Magaki
IPC分类号： G01N33/53 , C12Q1/02 , G01N33/566 , G01N33/00 , C07K16/18
CPC分类号： G01N33/6896 , G01N2800/2821 , G01N2800/2871
摘要： Low molecular weight (LMW) peptides have been discovered that are indicative of neurological conditions, such as Alzheimer's Disease (AD), cognitive impairment and brain microhemmorhages. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting neurological conditions and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting neurological conditions during the early stages without invasive procedures.
摘要翻译：已经发现了低分子量（LMW）肽，其指示诸如阿尔茨海默氏病（AD），认知障碍和脑微血管损伤之类的神经病学状况。评估患者样本中存在这样的LMW肽是检测神经系统疾病和监测疾病进展的有效手段。 LMW肽特别可用于在早期阶段检测神经系统疾病而无侵入性手术。

2. 发明申请

US20130137094A1 One-Step Cell and Tissue Preservative for Morphologic and Molecular Analysis 审中-公开
标题翻译：一步细胞和组织防腐剂用于形态和分子分析
公开(公告)号：US20130137094A1
公开(公告)日：2013-05-30
申请号：US13575001
申请日：2011-01-25
申请人： Virginia A. Espina , Lance A. Liotta , Claudius Mueller
发明人： Virginia A. Espina , Lance A. Liotta , Claudius Mueller
IPC分类号： G01N1/30
CPC分类号： G01N1/30 , A01N1/00
摘要： The invention relates to a one-step chemical composition that preserves animal tissue, cells, and biomolecules, such as human tissue, human cells, and biomolecules therein. It improves the fidelity and morphologic structure of cells, organelles, and nuclear chromatin, and maintains and enhances the cellular antigenicity for immunohistochemistry and flow cytometry, while preserving proteins, post-translational modifications of proteins, and nucleic acids. In one embodiment, the composition comprises a) a non-aldehyde precipitating fixative at a concentration below 25% (volume/volume), b) a reversible/cleavable protein cross-linker that targets lipid-associated molecules, and c) a c reversible/cleavable protein cross-linker that targets water soluble molecules. In another embodiment, the composition further includes a kinase inhibitor, a phosphatase inhibitor, and a permeation enhancer. In still another embodiment, the compositions further include lactic acid at a concentration sufficient to maintain cellular nuclear volume at a level equivalent to aldehyde fixation of the same type of cell. In a further embodiment, the composition comprises: a) a precipitating fixative, b) a reversible/cleavable cross-linker, c) a permeation enhancer, d) a kinase inhibitor, e) a phosphatase inhibitor, and f) a carboxylic acid. In a still further embodiment, the invention comprises method for preserving a biological sample by contacting the sample with the composition of the invention under conditions effective for the preservation of the sample.
摘要翻译：本发明涉及保留动物组织，细胞和生物分子的一步化学组合物，例如人组织，人细胞和生物分子。它提高细胞，细胞器和核染色质的保真度和形态结构，并保持和增强免疫组织化学和流式细胞术的细胞抗原性，同时保留蛋白质，蛋白质的翻译后修饰和核酸。在一个实施方案中，组合物包含a）浓度低于25％（体积/体积）的非醛沉淀固定剂，b）靶向脂质相关分子的可逆/可切割蛋白质交联剂，以及c）可逆可逆/ 可裂解的蛋白质交联剂，其靶向水溶性分子。在另一个实施方案中，组合物还包含激酶抑制剂，磷酸酶抑制剂和渗透增强剂。在另一个实施方案中，组合物还包括浓度足以将细胞核体积保持在与相同类型细胞的醛固定相当的水平的乳酸。在另一个实施方案中，组合物包括：a）沉淀固定剂，b）可逆/可切割交联剂，c）渗透促进剂，d）激酶抑制剂，e）磷酸酶抑制剂，和f）羧酸。在又一个实施方案中，本发明包括通过在有效保存样品的条件下使样品与本发明的组合物接触来保存生物样品的方法。

3. 发明申请

US20120083422A1 Glioblastoma Biomarkers, and Methods and Compositions 审中-公开
标题翻译：胶质母细胞瘤生物标记物，方法和组合物
公开(公告)号：US20120083422A1
公开(公告)日：2012-04-05
申请号：US13152204
申请日：2011-06-02
申请人： Claudius Mueller , Lance Liotta , Emanuel Petricoin , Virginia Espina
发明人： Claudius Mueller , Lance Liotta , Emanuel Petricoin , Virginia Espina
IPC分类号： C12Q1/02 , C40B30/04 , C40B30/06
CPC分类号： G01N33/57407 , G01N2800/52
摘要： Glioblastoma multiforme biomarkers, methods, and compositions are provided. Methods of selecting a treatment for a patient with a brain neoplasm, including Glioblastoma multiforme, are provided. Methods of treating a patient at risk for Glioblastoma multiforme are provided.
摘要翻译：提供多形性成胶质细胞瘤生物标志物，方法和组合物。提供了选择对包括多形性成胶质细胞瘤在内的脑肿瘤患者的治疗方法。提供了治疗多形性成胶质细胞瘤风险的患者的方法。

4. 发明申请

US20130023428A1 BIOMARKERS FOR NEUROLOGICAL CONDITIONS 审中-公开
标题翻译：生物标志物用于神经病学条件
公开(公告)号：US20130023428A1
公开(公告)日：2013-01-24
申请号：US13393817
申请日：2010-09-02
申请人： Claudius Mueller , Matthew Schrag , Lance Liotta , Wolff M. Kirsch , Harry V. Vinters
发明人： Claudius Mueller , Matthew Schrag , Lance Liotta , Wolff M. Kirsch , Harry V. Vinters
IPC分类号： C40B30/04 , C40B40/10 , G01N33/573 , G01N33/566 , G01N27/62
CPC分类号： G01N33/6896 , G01N2800/2821 , G01N2800/56 , G01N2800/60
摘要： Methods and kits for identifying and/or monitoring neurological conditions in a patient using ratios of biomarkers are disclosed. The neurological conditions may include, for example, Alzheimer's disease or mild cognitive impairment. The particular biomarkers that may be useful in identifying and/or monitoring neurological conditions may include, for example, biliverdin reductase, biliverdin reductase, estrogen receptor alpha, superoxide dismutase, S100A7, hemeoxygenase 1, matrix metalloproteinase 9 and platelet derived growth factor receptor. In particular, ratios of these biomarkers are useful.
摘要翻译：公开了使用生物标志物比例鉴定和/或监测患者神经系统状况的方法和试剂盒。神经病症可包括例如阿尔茨海默病或轻度认知障碍。可用于鉴定和/或监测神经病症的特定生物标志物可包括例如胆红素还原酶，胆红素还原酶，雌激素受体α，超氧化物歧化酶，S100A7，血液氧合酶1，基质金属蛋白酶9和血小板衍生生长因子受体。特别地，这些生物标志物的比例是有用的。

5. 发明授权

US09746458B2 Dynactin subunit p62 biomarker for neurological conditions 有权
公开(公告)号：US09746458B2
公开(公告)日：2017-08-29
申请号：US13457352
申请日：2012-04-26
申请人： Wolff M. Kirsch , Matthew Schrag , Andrew Crofton , Matthew Zabel , Claudius Mueller
发明人： Wolff M. Kirsch , Matthew Schrag , Andrew Crofton , Matthew Zabel , Claudius Mueller
IPC分类号： G01N33/50 , G01N33/566 , G01N33/84
CPC分类号： G01N33/5058 , G01N33/566 , G01N33/84 , G01N2500/10 , G01N2800/2821
摘要： Methods and kits for identifying neurological conditions in a patient by determining a level of expression of dynactin subunit p62 are disclosed. The neurological conditions may include, for example, Alzheimer's Disease (AD) without cerebral amyloid angiopathy (CAA).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式